secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-10-27T10:06:18+00:00
Accession:  0001104659-26-118952
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Aclaris ATI-052 Phase 1b hits: 45% placebo-adjusted EASI in AD, 59% FeNO cut in asthma
--------------------------------------------------------------------------------

- AD: ATI-052 480 mg weekly cut EASI 58% vs 13% placebo at day 57, a 45% placebo-adjusted mean improvement; EASI-50 was 78% placebo-adjusted.
- Itch: PP-NRS improved 43% placebo-adjusted at day 57 (38% active vs 5% worsening placebo); 33% achieved placebo-adjusted PP-NRS4 response.
- Asthma: single 480 mg dose cut FeNO 59% (45 ppb) at day 15 vs 15% placebo; 58% reached FeNO ≤25 ppb; FEV1 improved 200 mL placebo-adjusted.
- Safety: no Grade 3/4 TEAEs, no discontinuations, no conjunctivitis; injection-site reactions transient and mostly Grade 1.
- Aclaris will prioritize ATI-052 in eosinophilic esophagitis, planning a Phase 2b trial in early 2027; preliminary cash was $204.6M at Sept 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/0001104659-26-118952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/acrs-20261027x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-118952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer